Woody Joseph Fralin purchased $42K of RCEL

Woody Joseph Fralin purchased 10,000 shares of AVITA Medical, Inc. (RCEL) at an average of $4.19 ($4.18–$4.20) across 2 trades on 2026-06-09.

Original reporting
SEC EDGAR · Woody Joseph Fralin
Published Jun 9, 2026, 8:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RCEL
Bullish
medium confidence
Mentioned
$RCEL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCELBullishLow
01

Why it matters

A director’s open-market purchase is a new, primary datapoint that can slightly influence sentiment, but it does not change fundamentals by itself.

02

Market read

Traders may treat this as a small bullish signal, but it is unlikely to be a standalone driver of price action.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still doesn’t explain motivation; traders should avoid extrapolating without corroborating catalysts (trial/regulatory/financing).

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-09 (same day as the open-market purchase)

Background

The article is an SEC Form 4 insider transaction disclosure for Avita Medical, Inc. (RCEL).

Company-level read

Ticker impact

$RCELBullishMedium confidence
Context

Director Woody Joseph Fralin bought 10,000 shares of Avita Medical (RCEL) in open-market trades at ~$4.18–$4.20 on 2026-06-09.

Expected impact

Likely limited near-term impact; may add incremental bullish sentiment rather than a catalyst-driven repricing.

Evidence & confidence

Form 4 is primary-source and same-day, but the transaction value (~$41.9k) is small versus typical institutional/flow-driven moves and provides no operational or guidance change.

Market effects

No direct sector read-through; this is company-specific insider activity without new clinical/regulatory datapoints.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (e.g., personal liquidity needs, diversification, or non-informational timing) and may not signal fundamental upside.

Key entities

  • AVITA Medical, Inc.

    RCEL, the company whose director insider purchase was disclosed via SEC Form 4.

  • Woody Joseph Fralin

    Director who purchased 10,000 shares of RCEL on 2026-06-09.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RCELMed

Avita Medical Q3 Earnings Call Highlights

Avita Medical (RCEL) reported Q3 revenue of $600,000 for PermeaDerm, stable from Q2. Gross margin rose to 84%, and net loss narrowed to $6.2M. The company secured $10M in credit and alleviated going-concern doubts. RECELL revenue and manufacturing efficiencies drove improvements.

$RCELMed

AVITA Medical Reports Third Quarter Results

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Third Quarter Results Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., November 5, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic a

$RCELMedAI 8/10

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%

Avita Medical (NASDAQ:RCEL) reported Q2 net loss of $7.7M, nearly $3M better than Q1, with cash use down to $3.2M and cash of $11.1M at quarter end. The company raised its 2026 revenue outlook and said it is within Perceptive Advisors debt revenue covenants, including a $73M 2026 target. Q2 sales rose 18%.